Champions Oncology to announce Q4 and FY26 results on July 27
Champions Oncology, Inc. will announce its financial results for the quarter and year ended April 30, 2026, on July 27, 2026. A conference call is scheduled for 4:30 P.M. ET to discuss the outcomes. Replay options will be available via phone and the company's website.
*this image is generated using AI for illustrative purposes only.
Champions Oncology, Inc. will announce its financial and operational results for the quarter and year ended April 30, 2026, on Monday, July 27, 2026. The report will be released after the market closes, providing stakeholders with insights into the company's performance for the period.
To discuss the results, Champions Oncology will host a conference call on the same day at 4:30 P.M. ET (1:30 P.M. PT). Participants can join the call by dialing 888-506-0062 for domestic access or 973-528-0011 for international access, using the access code 347142.
A replay of the conference call will be made available within 72 hours. Interested parties can access the replay by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode 54320. The replay will also be accessible in the investors section of the company's website.
Conference Call Details
| Feature | Details |
|---|---|
| Date | July 27, 2026 |
| Time | 4:30 P.M. ET (1:30 P.M. PT) |
| Domestic Dial-in | 888-506-0062 |
| International Dial-in | 973-528-0011 |
| Access Code | 347142 |
Replay Information
| Feature | Details |
|---|---|
| Domestic Replay | 877-481-4010 |
| International Replay | 919-882-2331 |
| Passcode | 54320 |
Champions Oncology is a global preclinical and clinical research services provider, offering end-to-end oncology R&D solutions and data platforms to biopharma organizations. The company operates the largest annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models.
What strategic initiatives will Champions Oncology prioritize to drive growth in fiscal 2026?
How might the company's PDX and hematological malignancy models influence partnerships with biopharma organizations?
What market trends in oncology R&D could impact Champions Oncology's performance in the coming quarters?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
